29718 Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than August 24, 2009. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14708 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 13, 2009, 

Austin Pharma LLC., 811 Paloma Drive, 

Suite A, Round Rock, Texas 78665– 

2402, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Alphamethadol (9605) .................. I 

Nabilone (7379) ............................ II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

Levo-alphacetylmethadol (9648) .. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

Any other such applicant, and any 

person who is presently, registered with 

DEA to manufacture such substances 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than August 24, 2009. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator/Deputy Chief 

of Operation, Office of Diversion Control, 

Drug Enforcement Administration. 

[FR Doc. E9–14697 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Cooperative Research 

Group on Clean Diesel V 

Correction 

In notice document E9–10358 

appearing on page 21403 in the issue of 

May 7, 2009, make the following 

correction: 

On page 21403, in the first column, in 

the second line from the bottom, 

‘‘Auburn Hills, NI’’ should read 

‘‘Auburn Hills, MI’’. 

[FR Doc. Z9–10358 Filed 6–22–09; 8:45 am] 

BILLING CODE 1505–01–D 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations 1301.34(a), 

this is notice that on May 18, 2009, 

Aptuit, 10245 Hickman Mills Drive, 

Kansas City, Missouri 64137, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of 

Marihuana (7360), a basic class of 

controlled substance listed in schedule 

I. 

The company plans to import a 

finished pharmaceutical product 

containing cannabis extracts in dosage 

form for packaging for a clinical trial 

study. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than July 23, 2009. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import the basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14693 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations 1301.34(a), 

this is notice that on May 28, 2009, 

Boehringer Ingelheim Chemicals, Inc., 

2820 N. Normandy Drive, Petersburg, 

Virginia 23805, made application by 

renewal to the Drug Enforcement